Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 12;7(7):89.
doi: 10.3390/antiox7070089.

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials

Affiliations
Free PMC article
Review

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials

Gina Nauman et al. Antioxidants (Basel). .
Free PMC article

Abstract

Background: Ascorbate (vitamin C) has been evaluated as a potential treatment for cancer as an independent agent and in combination with standard chemotherapies. This review assesses the evidence for safety and clinical effectiveness of intravenous (IV) ascorbate in treating various types of cancer.

Methods: Single arm and randomized Phase I/II trials were included in this review. The PubMed, MEDLINE, and Cochrane databases were searched. Results were screened by three of the authors (GN, RP, and CJP) to determine if they met inclusion criteria, and then summarized using a narrative approach.

Results: A total of 23 trials involving 385 patients met the inclusion criteria. Only one trial, in ovarian cancer, randomized patients to receive vitamin C or standard of care (chemotherapy). That trial reported an 8.75 month increase in progression-free survival (PFS) and an improved trend in overall survival (OS) in the vitamin C treated arm.

Conclusion: Overall, vitamin C has been shown to be safe in nearly all patient populations, alone and in combination with chemotherapies. The promising results support the need for randomized placebo-controlled trials such as the ongoing placebo-controlled trials of vitamin C and chemotherapy in prostate cancer.

Keywords: ascorbate; cancer; clinical trials; intravenous; patients; vitamin C.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prisma Flow Diagram.
Figure 2
Figure 2
This figure represents the total number of cancer patients (n = 185) that were treated with intravenous ascorbic acid within the clinical trials summarized in this paper. This figure does not include patients who were enrolled in trials that used arsenic trioxide.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. McCormick W. Cancer: The preconditioning factor in pathogenesis; a new etiologic approach. Arch. Pediatr. 1954;71:313–322. - PubMed
    1. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O’Connell M.J., Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N. Engl. J. Med. 1985;312:137–141. doi: 10.1056/NEJM198501173120301. - DOI - PubMed
    1. Cimmino L., Dolgalev I., Wang Y., Yoshimi A., Martin G.H., Wang J., Ng V., Xia B., Witkowski M.T., Mitchell-Flack M., et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017;170:1079–1095. doi: 10.1016/j.cell.2017.07.032. - DOI - PMC - PubMed
    1. Cameron E., Pauling L. The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem. Biol. Interact. 1974;9:273–283. doi: 10.1016/0009-2797(74)90018-0. - DOI - PubMed
    1. Cameron E., Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem. Biol. Interact. 1974;9:285–315. doi: 10.1016/0009-2797(74)90019-2. - DOI - PubMed
Feedback